Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Inhibition of in vitro donor-specific proliferative and cytotoxic T cell responses in chimeric CD40 ligand-deficient bone marrow transplant recipients treated perioperatively with CTLA4-Ig.

Woodward JE, Schaefer AT, Zottola LB, Stazer JK, Logar AJ, Peach R, Rao AS.

Transplant Proc. 2001 Feb-Mar;33(1-2):113-4. No abstract available.

PMID:
11266733
2.

Blockade of the CD28/B7 pathway is required for the establishment of donor cell chimerism in CD40 ligand-deficient recipients.

Woodward JE, Zottola LB, Schaefer AT, Logar AJ, Stazer JK, Daskivich T, Peach R, Rao AS.

Transplant Proc. 2001 Feb-Mar;33(1-2):115. No abstract available.

PMID:
11266734
3.
4.

A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts.

Li S, Thanikachalam M, Pang M, Kawaharada N, Aitouche A, Pham SM.

Ann Thorac Surg. 2001 Oct;72(4):1306-10.

PMID:
11603451
5.

Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression.

Adams AB, Durham MM, Kean L, Shirasugi N, Ha J, Williams MA, Rees PA, Cheung MC, Mittelstaedt S, Bingaman AW, Archer DR, Pearson TC, Waller EK, Larsen CP.

J Immunol. 2001 Jul 15;167(2):1103-11.

6.

CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.

Pearson TC, Alexander DZ, Hendrix R, Elwood ET, Linsley PS, Winn KJ, Larsen CP.

Transplantation. 1996 Apr 15;61(7):997-1004.

PMID:
8623206
7.
8.

Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death.

Wekerle T, Kurtz J, Sayegh M, Ito H, Wells A, Bensinger S, Shaffer J, Turka L, Sykes M.

J Immunol. 2001 Feb 15;166(4):2311-6.

9.

Aggressive skin allograft rejection in CD28-/- mice independent of the CD40/CD40L costimulatory pathway.

Ha J, Bingaman AW, Durham MM, Pearson TC, Larsen CP.

Transpl Immunol. 2001 Oct;9(1):13-7.

PMID:
11680567
10.

Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment.

Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, Shaffer J, Sayegh MH, Sykes M.

Nat Med. 2000 Apr;6(4):464-9.

PMID:
10742157
11.

Transplantation of anergic histoincompatible bone marrow allografts.

Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG.

N Engl J Med. 1999 Jun 3;340(22):1704-14.

12.

Transplantation and the CD28/CTLA4/B7 pathway.

Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J.

Transplant Proc. 2001 Feb-Mar;33(1-2):209-11. No abstract available.

PMID:
11266782
13.

Mechanisms of donor-specific tolerance in a skin transplantation model.

van Pel M, Vingerhoed J, de Vries-van der Zwan A, van der Pol MA, Boog CJ.

Transplant Proc. 2001 Feb-Mar;33(1-2):152-3. No abstract available.

PMID:
11266754
17.

Viral abrogation of stem cell transplantation tolerance causes graft rejection and host death by different mechanisms.

Forman D, Welsh RM, Markees TG, Woda BA, Mordes JP, Rossini AA, Greiner DL.

J Immunol. 2002 Jun 15;168(12):6047-56.

19.

Role of STAT6 signaling in the induction and long-term maintenance of tolerance mediated by CTLA4-Ig.

Zhou P, Szot G, Guo Z, Kim O, He G, Wang J, Grusby M, Newell K, Thistlethwaite J, Bluestone J, Alegre M.

Transplant Proc. 2001 Feb-Mar;33(1-2):214-6. No abstract available.

PMID:
11266784
20.

Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning.

Luo B, Nanji SA, Schur CD, Pawlick RL, Anderson CC, Shapiro AM.

Transplantation. 2005 Aug 15;80(3):370-7.

PMID:
16082333

Supplemental Content

Support Center